Zhaohui Wang, Rashmi Ramakrishna, Yong Wang, Yue Qiu, Jihong Ma, Danielle Mintzlaff, Huiping Zhang, Bing Li, Benjamin Hammell, M Scott Lucia, Elizabeth Pomfret, An-Jey Su, Kia M Washington, David W Mathes, Zhirui Wang
We have developed a diphtheria toxin-based recombinant human CCR4-IL2 bispecific immunotoxin (CCR4-IL2-IT) for targeted therapy of cutaneous T-cell lymphoma (CTCL). CCR4-IL2-IT demonstrated superior efficacy in an immunodeficient mouse CTCL model. Recently, we have compared the in vivo efficacy of CCR4-IL2-IT versus Brentuximab (FDA approved leading drug in CTCL market) in the same immunodeficient mouse CTCL model. The comparison demonstrated that CCR4-IL2-IT was significantly more effective than Brentuximab...
February 15, 2024: European Journal of Pharmacology